

Patient Demographic Information

Last Name:		First Name:	
Address:		Apt #:	
City:		State:	Zip:
Primary Phone:		Alt Ph or Email:	
Height:	Weight (kg):	Sex: Male Female	DOB:
Emergency Contact:		Phone:	

Insurance Information

Primary Insurance Provider:	Policy Number:
Phone Number:	Group:
Secondary Insurance Provider:	Policy Number:
Phone Number:	Group:
Employer Name:	Phone Number:

Diagnosis/General Information

Allergies: _____ Pertinent Clinical History: _____ Patient Status (select one): New to therapy Continuation of therapy and last infusion day: _____ Please include the below information in the referral: Demographics Insurance Information Prescription/Order Clinicals showing infusion need: progress notes and diagnostics (i.e. EMG, Lumbar Puncture/Spinal Tap, MRI, nerve-conduction studies, etc.) Labs Additional Information: _____	Patient Diagnosis, ICD-10 Codes: G04.00 – G04.02 Acute disseminated encephalomyelitis (ADEM) G04.81 Autoimmune encephalitis G13.0 Paraneoplastic neurologic syndrome G25.82 Stiff person syndrome G35.A Relapsing-remitting multiple sclerosis G35.B0 Primary progressive multiple sclerosis unspecified G35.B1 Active primary progressive multiple sclerosis G36.0 Neuromyelitis optica spectrum disorder G61.0 Guillain-Barré syndrome (GBS) G61.81 Chronic inflammatory demyelinating polyneuropathy (CIDP) G61.82 Multifocal motor neuropathy (MMN) G70.00 Myasthenia gravis without exacerbation G70.01 Myasthenia gravis with exacerbation/crisis G72.41 Inclusion body myositis G73.1 Lambert-Eaton syndrome M33.00 – M33.99 Dermatomyositis M33.20 – M33.29 Polymyositis Other: _____
---	--

Prescription Information

Immunoglobulin (IVIG or SQIG)	_____ gm/kg over _____ days every _____ weeks	IVIG	SQIG
Briumvi	Initial: 150mg IV on Day 1, followed by 450mg once 2 weeks later	Maintenance: 450mg IV every 24 weeks (beginning 24 weeks after the 1st dose of 150mg)	
Imaavy	Initial: 30mg/kg IV X 1 dose	Maintenance: 15mg/kg IV every 2 weeks (starting 2 weeks after the initial dose)	
Ocrevus	Initial: 300mg IV on Day 1, followed by 300mg once 2 weeks later	Maintenance: 600mg IV every 6 months (beginning 6 months after the 1st 300mg dose)	
Ocrevus Zunovo	Ocrevus Zunovo 920mg/hyaluronidase 23,000 units SQ once every 6 months		
SoluMedrol	Solumedrol _____ mg IV daily x _____ day		
Soliris	Soliris 900 mg IV weekly x 4 weeks, 1200 mg IV on week 5 and every 2 weeks thereafter	If patient less than 40 kg, pharmacist to dose Patient weight: _____	
Ultomiris	Ultomiris _____ mg IV loading dose x1, then _____ mg IV two weeks after loading dose and every 8 weeks thereafter	Pharmacist to Dose: (Please fill in patient weight) Patient weight: _____	
Vyvgart	Vyvgart 10mg/kg IV (Greater than 120kg, dose is 1200mg) once weekly X 4 weeks. Repeat every _____ weeks		
Vyvgart Hytrulo	Vial For gMG: 1008mg Vyvgart Hytrulo alfa/11,200 units hyaluronidase SQ once weekly X 4 weeks. Repeat every _____ weeks	Vial For CIDP: 1008mg Vyvgart Hytrulo alfa/11,200 units hyaluronidase SQ once weekly	

Prescription Information Continued

Other Infusion medication (include dosing, frequency, and other pertinent information)

Prescription Order

Pre-Medication: Premedication and anaphylaxis kit per AOM Infusion protocol unless otherwise stated.

Diphenhydramine PO or IV _____ mg, 15-30 minutes prior to each infusion

Acetaminophen PO _____ mg tablet, 15-30 minutes prior to each infusion

Methylprednisolone IV _____ mg, 20 minutes prior to each infusion

Other _____ PO or IV, Strength _____ Directions _____

Other _____ PO or IV, Strength _____ Directions _____

None

Nursing and Lab Orders

Infusion Nursing: RN to provide start of care assessment, place PIV or access CVAD, administer all prescribed medication per Rx, monitor for adverse effects, and teaching until independent with procedure if applicable.

Labs: Lab draw requests will undergo review by the AOM clinical team to assess for current capacity and clinical appropriateness. Please note that we are unable to provide STAT Lab draws or Lab draws on weekends, holidays, or evenings due to specimen stability, logistics, and other considerations.

Lab Order _____ Frequency of Labs: Once Every Infusion Every _____ weeks

Lab Order _____ Frequency of Labs: Once Every Infusion Every _____ weeks

Prescriber Information

Prescriber:

Office Contact Name:

Clinic/Practice Name:

Address:

City:

State:

Zip:

Phone:

Fax:

License #:

UPIN #:

NPI:

Prescriber Signature: _____ **Date:** _____

Substitutions permitted unless "No Substitution" is noted on this form.

By signing this form, you and your practice are consenting to receive communications from AOM Infusion. You authorize AOM Infusion to assist with prior authorization requests acting as your pharmacy provider in dealing with prescription and medical insurance organizations.

This form is not a valid order in the state of Arizona.

CONFIDENTIALITY NOTICE: The information contained in this communication and any additional attachments is confidential information or Protected Health Information (PHI) belonging to the sender and intended only for the use of the individual or entity named above. If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this information in error, please notify AOM Infusion immediately at (800) 556-4246 to arrange for the return or destruction of the original document.

Fax completed form, insurance information, and clinical documentation to: **800-528-9860**. For any questions, please contact us at **800-746-9089** or visit our website **aominfusionrx.com**.